In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...

In justifying the government's termination of $500 million in funding for mRNA vaccine projects, Health and Human Services ...

COVID vaccines, including the new non-mRNA product Novavax, are safe and effective and decrease the burden of illness and ...

Federal vaccine policy changes under RFK Jr. have some concerned health insurance will not cover COVID shots. A bill in NY seeks to mandate coverage.

Clinical trials have shown the mRNA vaccines for COVID-19 are safe and effective, especially at preventing severe illness, hospitalization and death, according to the CDC. “During the COVID-19 ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

SHREVEPORT, La. - The U.S. Department of Health and Human Services has announced $500 million in funding cuts to vaccine ...

Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

The company, which is shifting its focus to commercializing vaccine candidates through partnerships, had licensed the rights ...